[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemoadsorption\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemoadsorption":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,83,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100647875","biological-effects-of-hemoadsorption-in-septic-shock-100647875",false,"NCT07715110","Biological Effects of Hemoadsorption in Septic Shock","Biological and Immunomodulatory Effect of Hemoadsorption With Macroporous Resin Cartridges in Septic Shock and Refractory Septic Shock Two Parallel Open-label Randomized Pilot Trials.","Bio-HA380","Inclusion Criteria:\n\n* All of the following:\n\n  * Age ≥ 18 years.\n  * Diagnosis of septic shock per Sepsis-3, with an identified or highly probable infectious focus.\n  * Meeting the operational definition of one of the two severity strata (SS or RSS) detailed in 6.1.\n  * Onset of septic shock within the last 24 hours (applied identically to both strata).\n  * Large-bore vascular access.\n  * Informed consent signed by the legal representative.\n\nExclusion Criteria:\n\n* Decision to limit life-sustaining therapy made or anticipated within the next 48 hours.\n* Absolute contraindication to anticoagulation with heparin and citrate.\n* Predominant non-septic shock (hemorrhagic, primary cardiogenic, obstructive).\n* Ongoing pregnancy.\n* Platelet count \\\u003C 20,000\u002FµL.\n* Significant pharmacological immunosuppression: chronic corticosteroids at doses \\> 20 mg\u002Fday prednisone equivalent, biologics within the last 6 months, cytotoxic chemotherapy within the last 4 weeks.\n* Solid organ or hematopoietic stem cell transplantation.\n* Concurrent participation in another clinical trial.","ALL","18 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"NA","Septic shock is the most severe form of sepsis and continues to carry an in-hospital mortality of between 30% and 50% despite advances in compliance with the Surviving Sepsis Campaign care bundles.\n\nThe pathophysiology of septic shock is dominated by an uncontrolled immuno-inflammatory response with massive release of mediators, pro- and anti-inflammatory cytokines5, DAMPs (damage-associated molecular patterns) and PAMPs (pathogen-associated molecular patterns), producing vasoplegia, endothelial dysfunction, glycocalyx damage and, in many patients, a subsequent immunoparalysis phase that increases the risk of nosocomial infections and late mortality.\n\nEndothelial damage and glycocalyx degradation are central elements in the pathophysiology of septic shock. The endothelial glycocalyx, a layer of proteoglycans and glycosaminoglycans approximately 0.5 µm thick on the luminal surface of the endothelium, regulates vascular permeability, leukocyte adhesion and the inflammatory response. During sepsis, the release of metalloproteinases, heparanase and other inflammatory mediators causes the shedding of syndecan-1, heparan sulfate and other glycocalyx molecules into the circulation. This process is associated with increased capillary permeability, interstitial edema, third-space fluid leakage, and progression to multiorgan failure. Elevated plasma syndecan-1 levels correlate with greater severity of septic shock, development of acute respiratory distress syndrome (ARDS), extrapulmonary organ dysfunction, and mortality. In parallel, the release of angiopoietin-2 by activated endothelial cells antagonizes Tie2 signaling, destabilizes the endothelial barrier and amplifies vascular dysfunction.\n\nSelective modulation of the immune response through extracorporeal adsorption of medium-sized mediators (5-60 kDa) is an adjunctive strategy whose biological rationale is well established and whose hemodynamic effect has been described by multiple authors. The HA380 HA cartridge (Jafron Biomedical), specifically, uses a synthetic neutral macroporous polymer resin with high affinity for cytokines in the 10-60 kDa range, especially IL-6, TNF-α, IL-8 and IL-10. The device is connected to an extracorporeal therapy circuit (in this protocol, always integrated into a continuous renal replacement therapy \\[CRRT\\] circuit) and operates for 4-6 hours per cartridge. Removal of proinflammatory cytokines (IL-6, TNF-α, IL-8) with HA380 also aims to reduce their effect on endothelial damage, and recent studies with other cytokine adsorbents have demonstrated the ability to remove circulating angiopoietin-2. Although the specific literature on the effect of HA380 on recovery of glycocalyx integrity is limited, reducing the burden of cytokines and endotoxic mediators could attenuate the glycocalyx degradation cascade and contribute to the hemodynamic stabilization observed in clinical studies. This mechanism provides an additional biological rationale for assessing biomarkers of endothelial dysfunction (angiopoietin-2, syndecan-1, soluble thrombomodulin) as secondary variables in the present study.\n\nWithin the spectrum of septic shock, this protocol distinguishes two clinically and biologically relevant severity strata: 1) established septic shock as per Sepsis-3 criteria who, despite requiring vasopressor support and showing hyperlactatemia, do not meet the thresholds of refractoriness. 2) refractory septic shock, a particularly severe subgroup in which standard resuscitation measures-guided fluid therapy, vasopressors, source control, early antibiotic therapy, and hydrocortisone-are insufficient to reverse tissue hypoperfusion and progressive organ dysfunction.\n\nPrimary objective To establish whether HA380 hemoadsorption yields a more desirable overall outcome than concurrent standard of care, within each severity stratum, using a pre-specified hierarchical ordinal DOOR endpoint.",[27,28,29,30,31],"Septic Shock, Vasopressor Resistance","Multiple Organ Dysfunction","Sepsis","Hemoperfusion","Hemoadsorption",[33,31,29,34,35,36],"Randomized","Septic shock","Refractory septic shock","Multiple Organ dysfunction","NOT_YET_RECRUITING","2026-07-15",{"date":40,"type":41},"2026-07-20","ACTUAL",{"date":43,"type":21},"2027-01-07",{"date":45,"type":21},"2029-06-30",{"name":47,"class":48},"Miguel Sanchez Garcia","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100645156","hemodynamic-laboratory-and-clinical-outcomes-of-hemoadsorption-therapy-100645156","NCT07679555","Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption Therapy","Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption theraPy: an obsErvational Study at Flór Ferenc Hospital Using Longitudinal Data (HOPE-FUL)","HOPE-FUL","Inclusion Criteria:\n\n* \\>18 years;\n* CytoSorb or Efferon LPS hemoadsorption treatment,\n* with available relevant pre- and post-treatment clinical and laboratory data\n\nExclusion Criteria:\n\n* age under 18 years\n* missing key demographic or outcome data;\n* unknown treatment type or timing;\n* data unavailable for legal or ethical reasons.",{"count":59,"type":21},60,"OBSERVATIONAL","This single-center retrospective observational cohort study aims to evaluate the clinical, hemodynamic, and laboratory effects of adjunctive hemoadsorption therapy in critically ill adult patients treated in the Intensive Care Unit of Flór Ferenc Hospital, Hungary, between January 1, 2020, and May 31, 2026. Patients who received CytoSorb® or Efferon LPS® hemoadsorption therapy will be included.\n\nThe study will assess changes in vasopressor requirements, hemodynamic parameters, inflammatory biomarkers, liver function tests, tissue perfusion markers, and oxygenation following hemoadsorption treatment. Clinical outcomes, including intensive care unit length of stay, all-cause mortality occurring during the patient's stay in the intensive care unit (ICU mortality), and 28-day and 90-day mortality, will also be evaluated. Data will be collected retrospectively from anonymized medical records, and no study-related interventions will be performed.",[31,63],"Vasopressor Therapy",[65,66,67,68,69,70,71],"hemoadsorption","CytoSorb","Efferon LPS","Vasoactive Inotropic Score","Vasopressor Dependency Index","Shock reversal time","Biomarkers","RECRUITING","2026-07-02",{"date":75,"type":41},"2026-07-07",{"date":77,"type":41},"2020-01-01",{"date":79,"type":21},"2026-09-30",{"name":81,"class":48},"Pest County Flór Ferenc Hospital",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":82},"100602743","hemoadsorption-for-severe-ischemic-stroke-100602743","NCT07127484","Hemoadsorption for Severe Ischemic Stroke","Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke","Inclusion Criteria:\n\n1.18 years ≤ age \\\u003C 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:\n\n1. 15≤ NIHSS score ≤32;\n2. 3\\\u003CGCS score ≤12;\n3. CT hypodensity area \\>1\u002F2 of the MCA territory; 4.hs-CRP ≥2 mg\u002FL at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation of PH2 type prior to randomization;\n2. Brain herniation or decompressive craniectomy performed before randomization;\n3. Hemodynamic instability refractory to medical correction (systolic blood pressure \\\u003C70 mmHg or diastolic blood pressure \\\u003C50 mmHg) or decompensated heart failure (NYHA Class III or IV);\n4. Severe hepatic impairment (defined as ALT \\>2 times the upper limit of normal or AST \\>2 times the upper limit of normal) and renal impairment (defined as serum creatinine \\>1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C50 mL\u002Fmin);\n5. Coagulopathy or thrombocytopenia (platelet count \\\u003C100×10⁹\u002FL);\n6. Deep vein thrombosis (DVT) of the lower extremities before randomization;\n7. Life expectancy \\\u003C90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials;\n9. Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant\u002Flactating women;\n10. Absolute contraindications to hemoadsorption therapy.","80 Years",{"count":92,"type":21},116,[24],"This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke",[96,31],"Ischemic Stroke","2026-05-13",{"date":99,"type":41},"2026-05-15",{"date":101,"type":41},"2026-01-05",{"date":103,"type":21},"2027-02-28",{"name":105,"class":48},"First Affiliated Hospital of Wannan Medical College",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":82},"100625220","oxiclear-oxiris-cytokines-and-endotoxin-adsorption-rate-study-100625220","NCT07419802","OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study","Endotoxin and Cytokine Adsorption Properties of the Oxiris Hemofilter in Septic Shock: Evaluation of Saturation Phenomena and Inflammatory Mediators' Clearance Capacity","OxiCLEAR","Inclusion Criteria (should meet all the criteria mentioned below):\n\n* Septic shock patient with a Dynamic scoring system of 6-8 points \u002FSeptic shock definition based on Sepsis-3: a vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate greater than 2mmol\u002FL despite optimal (30ml\u002Fkg body weight) bolus fluid resuscitation\u002F\n* CVVH with AN69-polyethylenimine (Oxiris) membrane for at least 24 hours\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Known contraindications to citrate anticoagulation\n* High likelihood of death within 24 hours due to irreversible comorbidities (e.g., end-stage cardiac, pulmonary, or hepatic disease; hepatorenal syndrome; advanced uncontrolled malignancy)\n* Simultaneous treatment with another adsorption device during the study period",{"count":115,"type":21},29,"This study examines how well the Oxiris® hemofilter works over time in adults with septic shock who require continuous kidney support in the intensive care unit (ICU).\n\nSeptic shock is a severe form of infection that leads to organ failure, including acute kidney injury. Many people with septic shock require continuous renal replacement therapy (CRRT), a form of dialysis that runs continuously to support the kidneys. The Oxiris® hemofilter is a special type of CRRT filter designed not only to replace kidney function but also to remove harmful substances from the blood, including endotoxins from bacteria and inflammatory proteins (cytokines).\n\nAlthough Oxiris® is widely used, it is not known how long the filter continues to remove these substances effectively. Over time, the membrane of the filter may become filled with endotoxins and cytokines, which could reduce its ability to clean the blood. This study aims to determine whether and when this loss of adsorption occurs during a standard twenty-four-hour treatment period.\n\nAdults with septic shock who receive Oxiris® as part of routine ICU care will take part in this observational study. No experimental treatment will be given. Blood samples will be taken before and after the filter, and fluid leaving the filter will be collected, to measure how endotoxins and cytokines are removed over time.\n\nThe study will also assess how changes in filter performance relate to clinical markers such as blood pressure support, blood lactate levels, organ function scores, kidney recovery, and twenty-eight-day survival.\n\nThe results will help define the optimal timing for Oxiris® filter replacement and support more effective use of blood purification therapy in patients with septic shock.",[29,118,119,31],"Septic Shock","Blood Purification",[121,122,65,123,124,125,126,127,128,129,130,131,132,133,134],"Oxiris","blood purification","septic shock","saturation phenomena","Continuous renal replacement therapy (CRRT)","AN69-polyethylenimine membrane","Endotoxin adsorption","Cytokine adsorption","Membrane saturation","Mass balance","Inlet-outlet concentration gradient","Membrane fouling","Precision blood purification","Endotoxemia","2026-02-16",{"date":137,"type":41},"2026-02-19",{"date":139,"type":21},"2026-03-01",{"date":141,"type":21},"2027-09-01",{"name":143,"class":48},"Pauls Stradins Clinical University Hospital"]